$RPHM News

Last published 2y ago

2y agoRPHM OKUROnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 MillionGlobeNewswire-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoinositide 3-kinase alpha (PI3Kα), initially in breast cancer -- On track to announce early clinical data for its lead
2y agoRPHMReneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKureGlobeNewswire– Combined company to trade on Nasdaq under ticker "OKUR" – Reneo announces 1-for-10 reverse split of common stock IRVINE, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) ("Reneo")
2y agoRPHMReneo Pharmaceuticals Reports Second Quarter 2024 Financial ResultsGlobeNewswireIRVINE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare
2y agoINFN RPHM PRFTKuehn Law Encourages INFN, RPHM, VAPO, and PRFT Investors to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may...
2y agoBATL DRQ PRFT RPHMKuehn Law Encourages BATL, DRQ, PRFT, and RPHM Investors to Contact Law FirmGlobeNewswireNEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoAIRC BCAL RPHM WIREKuehn Law Encourages BCAL, WIRE, RPHM, and AIRC Investors to Contact Law FirmGlobeNewswireNEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoALE HRT RPHM SQSPKuehn Law Encourages SQSP, HRT, RPHM, and ALE Investors to Contact Law FirmGlobeNewswireNEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
2y agoRPHMRPHM Alert: Monsey Firm of Wohl & Fruchter Investigating Proposed Merger of Reneo Pharmaceuticals With OnKureGlobeNewswireMONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) ("Reneo") with privately held OnKure, Inc.
2y agoRPHMReneo Pharmaceuticals and OnKure Announce Proposed MergerGlobeNewswireMerger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure's portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million
2y agoRPHMReneo Pharmaceuticals Reports First Quarter 2024 Financial ResultsGlobeNewswireIRVINE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare
2y agoRPHMReneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business UpdateGlobeNewswireIRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare
2y agoIPSC MIRM RPHM SGMTSagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of DirectorsGlobeNewswireSAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to
2y agoRPHMReneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)GlobeNewswireThe STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Reneo
2y agoRPHMReneo Pharmaceuticals Reports Third Quarter 2023 Financial ResultsGlobeNewswireIRVINE, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific MeetingsGlobeNewswireIRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)GlobeNewswireIRVINE, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro SummitGlobeNewswireIRVINE, Calif., Oct. 06, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals to Participate in Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals Reports Second Quarter 2023 Financial ResultsGlobeNewswireIRVINE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals to Participate in SVB Securities Therapeutics ForumGlobeNewswireIRVINE, Calif., June 30, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare,
3y agoRPHMReneo Pharmaceuticals Added to Russell 2000® and Russell 3000® IndicesGlobeNewswireIRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023GlobeNewswireIRVINE, Calif., June 15, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals to Participate at the Jefferies Healthcare ConferenceGlobeNewswireIRVINE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals Reports First Quarter 2023 Financial ResultsGlobeNewswireCompleted enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif., May 11, 2023
3y agoRPHMReneo Announces Pricing of Public Offering of Common StockGlobeNewswireIRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Reneo) (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients
3y agoRPHMReneo Pharmaceuticals Announces Proposed Public Offering of Common StockGlobeNewswireIRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Reneo) (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients
3y agoRPHMReneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewswireIRVINE, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial MyopathiesGlobeNewswireIRVINE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023GlobeNewswireIRVINE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
3y agoRPHMReneo Pharmaceuticals to Participate in SVB Securities Global Biopharma ConferenceGlobeNewswireIRVINE, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare,
3y agoRPHMReneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)GlobeNewswireIRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
4y agoRPHMReneo Pharmaceuticals Reports Third Quarter 2022 Financial ResultsGlobeNewswireIRVINE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare
4y agoRPHMReneo Pharmaceuticals to Participate at Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare,
4y agoRPHMReneo Pharmaceuticals to Participate at Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases,
4y agoRPHMReneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual MeetingGlobeNewswireIRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, a
4y agoRPHMReneo Pharmaceuticals Reports Second Quarter 2022 Financial ResultsGlobeNewswireIRVINE, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, to
4y agoRPHMReneo Pharmaceuticals Appoints Roshawn Blunt to its Board of DirectorsGlobeNewswireIRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, t
4y agoRPHMReneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development UpdatesGlobeNewswireLC-FAOD program to move forward into the next stage of clinical development Enrollment of pivotal STRIDE study in primary mitochondrial myopathies (PMM) patients with mitochondrial DNA (mtDNA) defects on track to be completed year-end 2022 Alignment w
4y agoRPHMReneo Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireIRVINE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, to
4y agoRPHMReneo Pharmaceuticals to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022)GlobeNewswireIRVINE, Calif., June 30, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, to
4y agoRPHMReneo Pharmaceuticals Reports First Quarter 2022 Financial ResultsGlobeNewswireIRVINE, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases, to
4y agoRPHMReneo Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdateGlobeNewswireIRVINE, Calif., March 23, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, t
4y agoRPHMReneo Pharmaceuticals Announces Senior Leadership PromotionsGlobeNewswireMichael P. Cruse appointed Chief Operating Officer Jennifer P. Lam appointed Principal Financial and Accounting Officer IRVINE, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutica
4y agoRPHMReneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare ConferenceGlobeNewswireIRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases,
4y agoRPHMReneo Pharmaceuticals Announces Changes to its Board of DirectorsGlobeNewswireIRVINE, Calif., Jan. 24, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases,
5y agoRPHMReneo Pharmaceuticals Reports Third Quarter 2021 Financial ResultsGlobeNewswireIRVINE, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic, mitochondrial diseases,
5y agoRPHMReneo Pharmaceuticals to Participate at Upcoming Investor ConferencesGlobeNewswireIRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases,
5y agoRPHMReneo Pharmaceuticals Announces Notice of Allowance for Patent Application on REN001GlobeNewswireIRVINE, Calif., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases,
5y agoRPHMReneo Pharmaceuticals Appoints Ashley Hall as Chief Development OfficerGlobeNewswireIRVINE, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, t